P Prokocimer

Summary

Publications

  1. doi request reprint Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial
    Philippe Prokocimer
    Trius Therapeutics Inc, 6310 Nancy Ridge Dr, Ste 104, San Diego, CA 92121, USA
    JAMA 309:559-69. 2013
  2. pmc Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections
    P Prokocimer
    Trius Therapeutics, Inc, 6310 Nancy Ridge Drive, Suite 105, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 55:583-92. 2011
  3. pmc In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions
    S Flanagan
    Trius Therapeutics, Inc, San Diego, California, USA
    Antimicrob Agents Chemother 57:3060-6. 2013

Collaborators

Detail Information

Publications3

  1. doi request reprint Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial
    Philippe Prokocimer
    Trius Therapeutics Inc, 6310 Nancy Ridge Dr, Ste 104, San Diego, CA 92121, USA
    JAMA 309:559-69. 2013
    ..Increasingly, ABSSSIs are associated with drug-resistant pathogens, and many antimicrobial agents have adverse effects restricting their use. Tedizolid phosphate is a novel oxazolidinone in development for the treatment of ABSSSIs...
  2. pmc Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections
    P Prokocimer
    Trius Therapeutics, Inc, 6310 Nancy Ridge Drive, Suite 105, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 55:583-92. 2011
    ..9 liters (35.7%). Results of this study show a high degree of efficacy at all three dose levels without significant differences in the safety profile and support the continued evaluation of TP for the treatment of cSSSI in phase 3 trials...
  3. pmc In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions
    S Flanagan
    Trius Therapeutics, Inc, San Diego, California, USA
    Antimicrob Agents Chemother 57:3060-6. 2013
    ..gov as NCT01539473 (tyramine interaction study conducted at Covance Clinical Research Center, Evansville, IN) and NCT01577459 (pseudoephedrine interaction study conducted at Vince and Associates Clinical Research, Overland Park, KS)...